Report
EUR 153.99 For Business Accounts Only

Moody's Ratings assigns a (P)Baa1 to Takeda and TUSFI's US shelf, Baa1 to TUSFI's USD notes, outlook stable (Japanese)

2025 年6月27日、 東京、 ムーディーズ・ ジャパン株式会社は、 Takeda U.S. Financing, Inc.( 以 下「TUSFI」) と武田薬品工業株式会社( 以下「武田薬品」、 Baa1 安定的) の発行登録枠に Baa1の格付を付与、 また、 TUSFIの米ドル建て信用補完付シニア無担保社債にBaa1の格付を付与し たことを公表した。 本邦法令上の格付付与日は2025年6月27日である。.
Underlying
Takeda Pharmaceutical Company Limited

Provider
Moody's Investors Service
Moody's Investors Service

Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:

  • 130 countries
    11,000 corporate issuers
    21,000 public finance issuers
    76,000 structured finance obligations



Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.



Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions. 

Other Reports on these Companies
Other Reports from Moody's Investors Service

ResearchPool Subscriptions

Get the most out of your insights

Get in touch